ArticlePloS one2026
Induction of osteogenic differentiation of MSCs by GSK3β knockdown through GSK3β siRNAs transfection.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of effective strategies for treating bone defects can be based on gene therapy methods aimed at regulating the differentiation of osteoprogenitor cells. One of the approaches is to use siRNA molecules in knockdown systems for genes inhibiting osteogenic cell differentiation. In this work, we aimed at developingapproaches to induce osteogenic differentiation of mesenchymal stem cells (MSCs) by siRNAs-mediated knockdown of GSK3β siRNAs in cultures of MSCs derived from human adipose tissue (AD-MSCs). For this purpose, we compared the transfection efficacy of lipoplexes and polyplexes formed with one of four siRNA molecules and five commercial transfection agents most commonly used in laboratory practice. The most effective transfection agent was found to be linear polyethylenimine (PEI) which demonstrated high cytocompatibility both in free form and in polyplexes (even when maximum concentrations were used). Using the polyplexes formed by the newly designed siRNA and PEI, we constructed a highly efficient GSK3β gene knockdown system, which showed effectiveness in AD-MSC cultures. As a result, we demonstrated the osteoinductive properties of GSK3β siRNA molecules in these cultures. These results provide a methodological basis for future siRNA-based strategies targeting GSK3β in osteogenic applications, with in vivo studies needed to establish its translational potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.